Shanghai Bio-heart Biological Technology Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Philip Wang
Chief executive officer
CN¥766.0k
Total compensation
| CEO salary percentage | 92.43% |
| CEO tenure | 10.4yrs |
| CEO ownership | 18.8% |
| Management average tenure | 4.3yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth
Nov 15
Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans
Jul 24Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth
Feb 22Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth
Nov 03We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth
May 12We're Not Worried About Shanghai Bio-heart Biological Technology's (HKG:2185) Cash Burn
Sep 19Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans
Jun 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | CN¥766k | CN¥708k | -CN¥88m |
| Sep 30 2024 | n/a | n/a | -CN¥102m |
| Jun 30 2024 | n/a | n/a | -CN¥116m |
| Mar 31 2024 | n/a | n/a | -CN¥146m |
| Dec 31 2023 | CN¥30m | CN¥708k | -CN¥176m |
| Sep 30 2023 | n/a | n/a | -CN¥182m |
| Jun 30 2023 | n/a | n/a | -CN¥189m |
| Mar 31 2023 | n/a | n/a | -CN¥197m |
| Dec 31 2022 | CN¥86m | CN¥708k | -CN¥204m |
| Sep 30 2022 | n/a | n/a | -CN¥234m |
| Jun 30 2022 | n/a | n/a | -CN¥263m |
| Mar 31 2022 | n/a | n/a | -CN¥312m |
| Dec 31 2021 | CN¥192m | CN¥709k | -CN¥361m |
| Sep 30 2021 | n/a | n/a | -CN¥437m |
| Jun 30 2021 | n/a | n/a | -CN¥512m |
| Mar 31 2021 | n/a | n/a | -CN¥419m |
| Dec 31 2020 | CN¥61m | CN¥491k | -CN¥326m |
| Dec 31 2019 | CN¥418k | CN¥418k | -CN¥24m |
Compensation vs Market: Philip's total compensation ($USD106.57K) is below average for companies of similar size in the Hong Kong market ($USD229.87K).
Compensation vs Earnings: Philip's compensation has been consistent with company performance over the past year.
CEO
Philip Wang (56 yo)
Mr. Li Wang, also known as Philip, serves as Executive Chairman of the Board and Chief Executive Officer at Shanghai Bio-heart Biological Technology Co., Ltd. and serves as its General Manager since July 1...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | no data | CN¥766.00k | 18.75% HK$ 117.3m | |
| CFO, Joint Company Secretary & Executive Director | 4.5yrs | CN¥1.20m | no data | |
| Financial Manager & Executive Director | 2.3yrs | CN¥808.00k | no data | |
| Chief Medical Officer | 4.2yrs | no data | no data | |
| Joint Company Secretary | 4.4yrs | no data | no data | |
| Chairperson of the Board of Supervisors & Head of Technology of BRS | no data | CN¥4.73m | no data |
Experienced Management: 2185's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 10.4yrs | CN¥766.00k | 18.75% HK$ 117.3m | |
| CFO, Joint Company Secretary & Executive Director | 4.7yrs | CN¥1.20m | no data | |
| Financial Manager & Executive Director | 2.5yrs | CN¥808.00k | no data | |
| Chairperson of the Board of Supervisors & Head of Technology of BRS | 4.4yrs | CN¥4.73m | no data | |
| Independent Non-Executive Director | 4.5yrs | CN¥268.00k | no data | |
| Independent Non-Executive Director | less than a year | CN¥78.00k | no data | |
| Supervisor | 2.5yrs | no data | no data | |
| Employee Representative Supervisor | 1.8yrs | no data | no data | |
| Independent Non-Executive Director | less than a year | CN¥78.00k | no data |
Experienced Board: 2185's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 05:59 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Bio-heart Biological Technology Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wen Dai | Huatai Research |
| Tielin Chen | Topsperity Securities |